Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 13/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5732152 | 0.91 | HMGCR (0.56) | HMGCR | |
| SCHEMBL5731745 | 0.83 | HMGCR (0.62) | HMGCRKDM4ESMN1; SMN2 | |
| SCHEMBL5731747 | 0.83 | HMGCR (0.62) | HMGCRKDM4ESMN1; SMN2 | |
| SCHEMBL5731742 | 0.83 | HMGCR (0.62) | HMGCRKDM4ESMN1; SMN2 | |
| SCHEMBL6091284 | 0.83 | HMGCR (0.50) | HMGCR | |
| SCHEMBL6090615 | 0.82 | HMGCR (0.49) | HMGCR | |
| SCHEMBL5731420 | 0.79 | HMGCR (0.45) | HMGCRKDM4ESMN1; SMN2 | |
| SCHEMBL5730836 | 0.79 | ALDH1A1 (0.42) | HMGCRNPC1RAB9AMAPTMEN1 | |
| SCHEMBL5731225 | 0.77 | HMGCR (0.56) | HMGCRNPC1RAB9AKMT2AKDM4E | |
| SCHEMBL5731467 | 0.77 | HMGCR (0.52) | HMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1691803-A1 | N-ALKYL PYRROLES AS HMG-COA REDUCTASE INHIBITORS | Warner-Lambert Company LLC (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20050154042-A1 | N-alkyl pyrroles as HMG-CoA reductase inhibitors | WARNER-LAMBERT COMPANY | 2005-07-14 | — | — | US | disclosed |
| WO-2005056004-A1 | N-ALKYL PYRROLES AS HMG-COA REDUCTASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154042-A1 | N-alkyl pyrroles as HMG-CoA reductase inhibitors | HMGCR, DHCR7, CYP11A1 | HMGCR 1/4885NPC1 45/4885RAB9A 3611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.